Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexamethasone + droperidol
- Development stage
- Phase 4
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination of dexamethasone (a corticosteroid) and droperidol (a butyrophenone derivative and dopamine antagonist) used primarily for the prevention and treatment of postoperative nausea and vomiting (PONV). Dexamethasone relieves inflammation while droperidol produces tranquilization and reduces nausea/vomiting by acting as a dopamine antagonist. The combination has an additive antiemetic effect, particularly when combined with ondansetron.
02
Targets
DRD2 (Dopamine D2 Receptor)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on dexamethasone + droperidol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexamethasone + droperidol.